West Pharmaceutical Services (WST) EBIT Margin (2009 - 2026)

West Pharmaceutical Services (WST) has reported EBIT Margin for 18 consecutive years, with 20.53% the latest figure, recorded in Q2 2026.

• Quarterly EBIT Margin rose 48.0% year-over-year to 20.53% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 20.45% (up 80.0% YoY) and the FY2025 annual result came in at 19.03%, down 67.0% from the prior year.
• EBIT Margin declined to 20.53% in Q2 2026 per WST's latest filing, from 20.96% in the prior quarter.
• Over the last five years, EBIT Margin for WST reached as high as 29.61% in Q2 2022 and fell as low as 15.33% in Q1 2025.
• A 5-year average of 21.59% and a median of 21.14% in 2024 frame the typical range for EBIT Margin.
• Annual changes were most pronounced in 2022 — EBIT Margin sank 688 bps — and 2026, when it soared 563 bps.
• Year by year, EBIT Margin stood at 18.3% in 2022, then rose by 20 bps to 21.98% in 2023, then fell by 3 bps to 21.31% in 2024, then slipped by 9 bps to 19.45% in 2025, then increased by 6 bps to 20.53% in 2026.
• According to Business Quant data, EBIT Margin over the past three periods registered 20.53%, 20.96%, and 19.45% for Q2 2026, Q1 2026, and Q4 2025 respectively.